{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:39:16Z","timestamp":1783658356449,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04465-7","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T07:08:40Z","timestamp":1745651320000},"page":"3543-3551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Short-term outcomes of triplet therapy in metastatic hormone-sensitive prostate cancer in older adults: a retrospective, single-center real-world cohort study"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8673-5170","authenticated-orcid":false,"given":"Kimitsugu","family":"Usui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Aigase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-9547","authenticated-orcid":false,"given":"Atsuto","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6016-108X","authenticated-orcid":false,"given":"Takeshi","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7228-3447","authenticated-orcid":false,"given":"Noboru","family":"Nakaigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"4465_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","volume":"81","author":"Q Cheng","year":"2022","unstructured":"Cheng Q, Butler W, Zhou Y et al (2022) Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol 81:446\u2013455. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.039","journal-title":"Eur Urol"},{"key":"4465_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77:38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005","journal-title":"Eur Urol"},{"key":"4465_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101194","author":"C Oing","year":"2023","unstructured":"Oing C, Bristow RG (2023) Systemic treatment of metastatic hormone-sensitive prostate cancer\u2014upfront triplet versus doublet combination therapy. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101194","journal-title":"ESMO Open"},{"key":"4465_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132\u20131142. https:\/\/doi.org\/10.1056\/NEJMoa2119115","journal-title":"N Engl J Med"},{"key":"4465_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicenter, open-label, randomized, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 399:1695\u20131707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1","journal-title":"Lancet"},{"key":"4465_CR6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.annonc.2021.06.003","volume":"32","author":"AA Hamid","year":"2021","unstructured":"Hamid AA, Huang HC, Wang V et al (2021) Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3085 CHAARTED trial. Ann Oncol 32:1157\u20131166. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.003","journal-title":"Ann Oncol"},{"key":"4465_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","volume":"9","author":"B Hoeh","year":"2023","unstructured":"Hoeh B, Garcia CC, Wenzel M et al (2023) Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: an updated network meta-analysis including ARANOTE data. Eur Urol Focus 9:838\u2013842. https:\/\/doi.org\/10.1016\/j.euf.2023.03.024","journal-title":"Eur Urol Focus"},{"key":"4465_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Naqvi SAA, He H et al (2023) First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. JAMA Oncol 9:635\u2013645. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7762","journal-title":"JAMA Oncol"},{"key":"4465_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.euros.2024.02.019","volume":"63","author":"P Rajwa","year":"2024","unstructured":"Rajwa P, Borkowetz A, Abbott T et al (2024) Research protocol for an observational health data analysis on the adverse events of systemic treatment in patients with metastatic hormone-sensitive prostate cancer: big data analytics using the PIONEER platform. Eur Urol Open Sci 63:81\u201388. https:\/\/doi.org\/10.1016\/j.euros.2024.02.019","journal-title":"Eur Urol Open Sci"},{"issue":"8","key":"4465_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101621","volume":"14","author":"M Fernando","year":"2023","unstructured":"Fernando M, Anton A, Weickhardt A et al (2023) Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort J Geriatr. Oncol 14(8):101621. https:\/\/doi.org\/10.1016\/j.jgo.2023.101621","journal-title":"Oncol"},{"key":"4465_CR11","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen Y-H, Carducci MA et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36:1080\u20131087. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657","journal-title":"J Clin Oncol"},{"issue":"1","key":"4465_CR12","doi-asserted-by":"publisher","first-page":"101411","DOI":"10.1016\/j.jgo.2022.11.010","volume":"14","author":"G Francolini","year":"2023","unstructured":"Francolini G, Frosini G, Di Cataldo V et al (2023) Predictive factors for tolerance to taxane-based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427). J Geriatr Oncol 14(1):101411","journal-title":"J Geriatr Oncol"},{"key":"4465_CR13","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","volume":"5","author":"AM Moilanen","year":"2015","unstructured":"Moilanen AM, Riikonen R, Oksala R et al (2015) Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 5:12007. https:\/\/doi.org\/10.1038\/srep12007","journal-title":"Sci Rep"},{"key":"4465_CR14","first-page":"23","volume":"1","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Hoeh B, Hurst F et al (2024) Impact of PSA nadir and PSA response on overall survival in metastatic hormone-sensitive prostate cancer. EAU Open Proc 1:23\u201331","journal-title":"EAU Open Proc"},{"key":"4465_CR15","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","volume":"27","author":"M Hussain","year":"2009","unstructured":"Hussain M, Goldman B, Tangen C et al (2009) Prostate-specific antigen (PSA) progression predicts overall survival in metastatic hormone-sensitive prostate cancer: Insights from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27:2450\u20132456. https:\/\/doi.org\/10.1200\/JCO.2008.19.9810","journal-title":"J Clin Oncol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04465-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04465-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04465-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:35:31Z","timestamp":1759844131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04465-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4465"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04465-7","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board of the Kanagawa Cancer Center (Approval No. 2023\u2013101) and was conducted in accordance with the provisions of the Declaration of Helsinki. The need for informed consent was waived owing to the retrospective nature of the study and the use of de-identified patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"An opt-out option was provided to the patient via the homepage of the hospital website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}